MX362271B - Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso. - Google Patents

Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.

Info

Publication number
MX362271B
MX362271B MX2013013855A MX2013013855A MX362271B MX 362271 B MX362271 B MX 362271B MX 2013013855 A MX2013013855 A MX 2013013855A MX 2013013855 A MX2013013855 A MX 2013013855A MX 362271 B MX362271 B MX 362271B
Authority
MX
Mexico
Prior art keywords
methods
cyclosporine
preparation
crystalline form
crystalline forms
Prior art date
Application number
MX2013013855A
Other languages
English (en)
Other versions
MX2013013855A (es
Inventor
Karami Kiomars
s graham Richard
V Gore Anuradha
W Smith Scott
Wu Ke
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46178866&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX362271(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2013013855A publication Critical patent/MX2013013855A/es
Publication of MX362271B publication Critical patent/MX362271B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona generalmente con formas cristalinas de ciclosporina A y particularmente con una forma nueva identificada de ciclosporina A. la invención se relaciona con métodos para su preparación y métodos para tratar algunos trastornos aculares.
MX2013013855A 2011-05-27 2012-05-25 Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso. MX362271B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490887P 2011-05-27 2011-05-27
PCT/US2012/039611 WO2012166610A1 (en) 2011-05-27 2012-05-25 A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof

Publications (2)

Publication Number Publication Date
MX2013013855A MX2013013855A (es) 2014-02-17
MX362271B true MX362271B (es) 2019-01-10

Family

ID=46178866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013855A MX362271B (es) 2011-05-27 2012-05-25 Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.

Country Status (19)

Country Link
US (4) US8772245B2 (es)
EP (2) EP3521302A1 (es)
JP (1) JP6163482B2 (es)
KR (1) KR102079402B1 (es)
CN (1) CN103649108B (es)
AR (1) AR086586A1 (es)
AU (4) AU2012262513B2 (es)
BR (1) BR112013030554B1 (es)
CA (1) CA2836946C (es)
CL (1) CL2013003400A1 (es)
IL (2) IL229475A0 (es)
MX (1) MX362271B (es)
MY (1) MY180581A (es)
RU (1) RU2602062C2 (es)
SG (1) SG10201607344UA (es)
TW (1) TWI554522B (es)
UA (1) UA113627C2 (es)
WO (1) WO2012166610A1 (es)
ZA (1) ZA201308665B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014011744A2 (pt) * 2011-11-15 2017-05-02 Allergan Inc formulação de ação sustentável da forma 2 de ciclosporina
EP2779994B1 (en) * 2011-11-15 2020-02-19 Allergan, Inc. Suspensions of cyclosporin a form 2
CN104039308B (zh) * 2011-11-15 2018-06-05 阿勒根公司 环孢菌素a形式2的可热压性悬浮液
US8796221B2 (en) 2011-11-15 2014-08-05 Allergan, Inc. Cyclosporin A form 2 and method of making same
WO2013181339A2 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
US10524661B2 (en) * 2013-06-12 2020-01-07 Proactive Live, Inc. Sleep monitoring and stimulation
KR20170030093A (ko) 2014-07-18 2017-03-16 알레간 인코포레이티드 결막하 및 눈주위 주사를 위한 사이클로스포린 a의 현탁액 조성물
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
US10443292B2 (en) * 2016-04-25 2019-10-15 Magna Closures, Inc. Non-contact obstacle detection system for motor vehicles
KR102287226B1 (ko) * 2017-05-17 2021-08-11 주식회사 유유제약 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
WO2024085235A1 (ja) * 2022-10-20 2024-04-25 中外製薬株式会社 環状ペプチドの結晶の製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203564B (en) * 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
AU2008247680A1 (en) 2007-05-04 2008-11-13 Allergan, Inc. Use of cyclosporines in the treatment of patients with intraocular lenses
CN101990437A (zh) * 2008-01-04 2011-03-23 阿尔康药品有限公司 稳定的环孢菌素水性组合物

Also Published As

Publication number Publication date
TW201311730A (zh) 2013-03-16
CA2836946A1 (en) 2012-12-06
AU2019204192B2 (en) 2021-02-04
MX2013013855A (es) 2014-02-17
AU2012262513B2 (en) 2016-03-17
UA113627C2 (xx) 2017-02-27
TWI554522B (zh) 2016-10-21
AR086586A1 (es) 2014-01-08
KR20140047054A (ko) 2014-04-21
SG10201607344UA (en) 2016-10-28
US20210269484A1 (en) 2021-09-02
CN103649108B (zh) 2017-03-29
ZA201308665B (en) 2014-07-30
NZ618213A (en) 2016-05-27
US20140315827A1 (en) 2014-10-23
NZ719272A (en) 2017-10-27
BR112013030554B1 (pt) 2020-12-15
AU2016203990A1 (en) 2016-06-30
IL290158A (en) 2022-03-01
AU2019204192A1 (en) 2019-07-04
EP3521302A1 (en) 2019-08-07
US20160083432A1 (en) 2016-03-24
CL2013003400A1 (es) 2014-08-18
RU2013155033A (ru) 2015-07-20
RU2602062C2 (ru) 2016-11-10
AU2017265008A1 (en) 2017-12-07
JP2014515372A (ja) 2014-06-30
US9206228B2 (en) 2015-12-08
JP6163482B2 (ja) 2017-07-12
US20130023482A1 (en) 2013-01-24
BR112013030554A2 (pt) 2016-09-06
EP2714720A1 (en) 2014-04-09
EP2714720B1 (en) 2018-12-26
WO2012166610A1 (en) 2012-12-06
KR102079402B1 (ko) 2020-02-19
CA2836946C (en) 2017-08-01
US8772245B2 (en) 2014-07-08
MY180581A (en) 2020-12-02
CN103649108A (zh) 2014-03-19
AU2012262513A1 (en) 2013-12-12
IL229475A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MX362271B (es) Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.
AU2018236800B2 (en) DNA-PK inhibitors
IL274469A (en) Compositions, uses and methods for the treatment of metabolic disorders and diseases
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
EP2938616A4 (en) PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES
EP2665696A4 (en) PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUOR-2-PROPENE
WO2013177133A3 (en) Generation of human ips cells by a synthetic self- replicative rna
EP2701721A4 (en) METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM OR OTHER DISORDERS
MX354988B (es) Formulaciones de anticuerpo y metodos.
WO2012106393A3 (en) Withanolide isolated from physalis longifolia and analogs and methods of use thereof
HK1200367A1 (en) 4-pregenen-11ss-17-21-triol-3, 20-dione derivatives for the treatment of ocular conditions 4--11ss-17-21--320-
WO2013034979A3 (en) Crystalline forms of cabazitaxel
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
IL232710A0 (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
WO2012112674A3 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
MX2013007567A (es) Procedimiento para preparar poliestereteroles.
IN2014DN06964A (es)
MX2013015347A (es) Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
WO2013155465A8 (en) Substituted xanthine derivatives
IN2014DN09451A (es)
EA201400606A1 (ru) Полиолефиновое волокно
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase

Legal Events

Date Code Title Description
FG Grant or registration